enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Rimonabant - Wikipedia

    en.wikipedia.org/wiki/Rimonabant

    Rimonabant is a selective CB 1 receptor blocker and was discovered and developed by Sanofi-Aventis. [6]On 21 June 2006, the European Commission approved the sale of rimonabant in the then-25-member European Union as a prescription drug for use in conjunction with diet and exercise for patients with a body mass index (BMI) greater than 30 kg/m 2, or patients with a BMI greater than 27 kg/m 2 ...

  3. JD5037 - Wikipedia

    en.wikipedia.org/wiki/JD5037

    JD5037 is an antiobesity drug candidate which acts as a peripherally-restricted cannabinoid inverse agonist at CB 1 receptors.It is very selective for the CB 1 subtype, with a Ki of 0.35nM, >700-fold higher affinity than it has for CB 2 receptors.

  4. AM-251 (drug) - Wikipedia

    en.wikipedia.org/wiki/AM-251_(drug)

    AM-251 is an inverse agonist at the CB 1 cannabinoid receptor. AM-251 is structurally very close to rimonabant; both are biarylpyrazole cannabinoid receptor antagonists.In AM-251, the p-chloro group attached to the phenyl substituent at C-5 of the pyrazole ring is replaced with a p-iodo group.

  5. Zevaquenabant - Wikipedia

    en.wikipedia.org/wiki/Zevaquenabant

    Zevaquenabant (S-MRI-1867, INV-101, or MRI-1867) is an investigational small-molecule drug, discovered by Dr George Kunos, Dr Resat Cinar, and Dr Malliga iyer at the National Institutes of Health. Zevaquenabant was described as a third generation cannabinoid receptor 1 (CB1R) antagonist due to its peripheral selectivity and polypharmacology . [ 1 ]

  6. Cannabinoid receptor antagonist - Wikipedia

    en.wikipedia.org/.../Cannabinoid_receptor_antagonist

    A cannabinoid receptor antagonist, also known simply as a cannabinoid antagonist or as an anticannabinoid, is a type of cannabinoidergic drug that binds to cannabinoid receptors (CBR) and prevents their activation by endocannabinoids. They include antagonists, inverse agonists, and antibodies of CBRs.

  7. Monlunabant - Wikipedia

    en.wikipedia.org/wiki/Monlunabant

    Monlunabant (INV-202, MRI-1891, or S-MRI-1891) is a peripherally selective cannabinoid receptor 1 inverse agonist, discovered as a β-arrestin-2-biased cannabinoid receptor 1 antagonist by Dr George Kunos, Dr Resat Cinar, and Dr Malliga Iyer at the National Institutes of Health. [1] It was developed as a weight loss drug by Inversago Pharma. [2 ...

  8. Drinabant - Wikipedia

    en.wikipedia.org/wiki/Drinabant

    Drinabant (INN; AVE-1625) is a drug that acts as a selective CB 1 receptor antagonist, which was under investigation varyingly by Sanofi-Aventis as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence.

  9. TM-38837 - Wikipedia

    en.wikipedia.org/wiki/TM-38837

    TM-38837 is a small molecule inverse agonist/antagonist of the CB 1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. [1] The company has announced phase I clinical trials.